Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021398 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 17
- Study locations
NCT00021398: Completed Phase 2 study of Colorectal Cancer, sponsored by Fox Chase Cancer Center.
NCT00021398 is a Phase 2 study of Colorectal Cancer that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 23 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021398, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 17
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and chemotherapy followed by surgery and combination chemotherapy in treating patients who have stage II or stage III rectal cancer.
Conditions Studied
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Study Locations (17)
Pennsylvania
- Bon Secours-Holy Family Health System - Altoona
- Delaware County Memorial Hospital - Drexel Hill
- Pinnacle Health Hospitals - Harrisburg
- Conemaugh Memorial Hospital - Johnstown
- Saint Mary Regional Center - Langhorne
- North Penn Hospital - Lansdale
- Paoli Memorial Hospital - Paoli
- Fox Chase Cancer Center - Philadelphia
- Pottstown Memorial Regional Cancer Center - Pottstown
- Reading Hospital and Medical Center - Reading
- Southern Chester County Medical Center - West Grove
New Jersey
- Hunterdon Regional Cancer Center - Flemington
- Kimball Medical Center - Lakewood
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County - Mount Holly
- Riverview Medical Center - Red Bank
- Community Medical Center - Toms River
- St. Francis Medical Center - Trenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 1996-07 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
What the finished NCT00021398 record still lists
NCT00021398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which fluorouracil is the first listed.
NCT00021398 lists 17 locations in 2 states (Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00021398 about?
NCT00021398 is a clinical study titled "Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may shrink the tumor so that it can be removed during surgery. PURPOS...
What is the current status of trial NCT00021398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 1996-07. Estimated completion is 2018-09.
What conditions does trial NCT00021398 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00021398?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00021398?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021398 being conducted?
This trial has 17 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00021398's enrollment target sits among peer trials
23 339th of 381 higher than 42 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia